Multi-omics analysis in EGFR-mutant lung adenocarcinoma

ABSTRACT: Using genomic and transcriptomic anaysis, we have identified TP53-GOF mutations as key genomic alterations associated with early resistance to first-line osimertinib therapy in EGFR-mutant NSCLC. Through comprehensive genomic and transcriptomic profiling, we found that TP53-GOF mutations define a biologically distinct subgroup marked by significantly shorter progression-free survival against osimrtinib treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE297057 | GEO | 2026/05/11

REPOSITORIES: GEO